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Abstract: At the time of this study, there were ﬁ  ve known patients with Wilson disease (WD) 
in Iceland. The mutation, a 7-bp deletion in exon 7 on chromosome 13 for WD, is only known 
in Iceland. In twenty healthy Icelandic heterozygotes for WD and their age- and gender-matched 
controls, copper concentration in plasma, ceruloplasmin (CP) concentration, CP oxidative 
activity and CP-speciﬁ  c oxidative activity in serum and superoxide dismutase (SOD1) activity 
in erythrocytes were determined. The same determinations were done on the ﬁ  ve WD patients. 
There was no signiﬁ  cant difference in these parameters between the heterozygotes and the 
controls, although an inclination toward lower CP determinations and higher SOD1 activity 
in the heterozygotes was noted. As expected the WD patients were low on the copper and CP 
parameters, but their SOD1 activity was within the upper normal range. In conclusion, the CP 
parameters and SOD1 activity are within the normal range in Icelandic heterozygotes for WD, 
although with a trend toward mild dyshomeostasis. This may indicate subclinical copper reten-
tion in the heterozygotes, but a bigger study group is needed to conﬁ  rm this.
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Introduction
Wilson disease (WD) is characterized by decreased biliary copper excretion and reduced 
incorporation of copper in apoceruloplasmin, resulting in lower levels of ceruloplasmin 
(CP) and copper in serum but copper accumulation in various organs and tissues. WD 
is an autosomal recessive disease of copper transport, and the gene for WD has been 
mapped to the short arm of chromosome 13.1 It was cloned and coded for as a putative 
copper transporting P-type ATPase (ATP7B).2,3 WD may present under a variety of clini-
cal symptoms, most commonly from liver and/or as neuropsychiatric disturbances.
The incidence of hypoceruloplasminemia in heterozygotes for WD is not known, 
but they usually have a normal CP concentration in serum, although it may be slightly 
reduced.4,5 The heterozygotes are most commonly clinically asymptomatic and have 
a normal copper concentration in serum. They may however, show some signs of 
disturbed copper metabolism. While patients with WD do not incorporate radioactive 
copper (64Cu and 67Cu) into CP, the heterozygotes incorporate the isotopes into CP at 
a rate between that of normal individuals and WD patients.4
Cu-Zn superoxide dismutase (SOD1) activity in erythrocytes is known to be 
lowered in copper deﬁ  ciency, but the correlation with copper and CP in serum is poor.6 
Copper-chelating treatment has been found to lower SOD1 activity in erythrocytes, 
and it was concluded that the SOD1 activity in erythrocytes reﬂ  ects the availability of 
intracellular copper.6 SOD1 activity was found to be the same in three untreated WD 
patients, compared with controls, but was lowered after treatment with D-penicillamine.7 
To our knowledge no study has been done on SOD1 in heterozygotes for WD.Neuropsychiatric Disease and Treatment 2009:5 56
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Gamma glutamyl transpeptidase (GGT) is localised 
predominantly within the cytoplasm of hepatocytes and 
biliary epithelial cells of the liver. It has been recognized as a 
useful marker of liver disease.8 As CP in serum is produced 
in hepatocytes, the determination of GGT activity in serum is 
of use, as damage of hepatocytes can be a cause for changes 
in CP parameters.
At the time of this study, there were ﬁ  ve living Wilson 
patients in Iceland. All of the known patients in Iceland 
have had the same mutation, a 7-bp deletion in exon 7 on 
chromosome 13, and this mutation is not known elsewhere 
in the world.9
This study was undertaken in order to elucidate whether 
the heterozygotes for the unique Icelandic type of WD had 
any particular derangement of their copper metabolism.
Material and methods
The ﬁ  ve known Icelandic WD patients and 20 healthy, 
ﬁ  rst-degree relatives of the WD patients (heterozygotes) were 
traced (parents, siblings, and children of the patients). The 
mean age of the heterozygotes was 41 years (range 21–70), 
nine males and 11 females. Each heterozygote had healthy 
age- and gender-matched control.
The blood samples were taken in the morning in the 
fasting state, and the blood sampling units used were 
specially prepared for metal analysis (Sarstédt®). The same 
blood sampling procedure was used for the WD patients, 
heterozygotes and controls. All the WD patients were on 
copper-chelating treatment.
The study was approved by the Icelandic National 
Bioethics Committee (01-056-S1) and registered by The 
Data Protection Authority.
Determination of gamma glutamyl 
transpeptidase
GGT activity in serum, expressed as units/l, was determined 
at the Icelandic University Hospital Laboratories, on Vitros 
950, Ortho-Clinical Diagnostics, Rochester, NY, USA. 
GGT catalyzes the transfer of the gamma-glutamyl portion 
of L-gamma-glutamyl-p-nitroanilide to glycylglycine, 
simultaneously producing p-nitroaniline. The rate of change 
in reﬂ  ection density is measured and used to calculate the 
enzyme activity of GGT. The upper limit of GGT in healthy 
subjects is 70 units/l at these laboratories.
Determination of copper in plasma
A solution of 0.5 ml plasma, 5 ml of double distilled water, 
0.2 ml of concentrated hydrochloric acid (Emerck, Darmstadt, 
100318) and 0.125 ml of concentrated nitric acid (E Merck, 
100456) was pipetted into a Teﬂ  on-lined microwave acid 
digestion bomb. The digestion bomb was heated in a 600 W 
microwave oven for 3.25 min. After cooling, 10 ml of distilled 
water were added and samples taken to analysis. A standard 
serum from Nycomed Pharma AS, Oslo, Norway, was processed 
in the same way. Copper in the samples (μmol/l plasma) was 
determined at the Icelandic Fisheries Laboratories, Reykjavík, 
by atomic absorption spectrophotometry.
Determination of CP concentration
Ceruloplasmin levels in serum (mg/l) were determined at 
the Icelandic University Hospital Laboratories with rate 
nephelometry immunoassay (Beckman Immunochemistry 
Systems, ICS-2 Beckman Instruments Inc.). The CP antibody 
was processed goat sera, which were calibrated with an Inter-
national Federation of Clinical Chemistry human calibrator. 
The results are represented as μmol/l in Table 1.
Determination of CP oxidative 
activity in serum
Ceruloplasmin oxidative activity in serum (units/ml) 
was determined at the Department of Pharmacology and 
Toxicology, University of Iceland, with the manual kinetic 
assay described by Boyett and colleagues.10 The method 
is based on the oxidative activity of CP with o-dianisidine 
as substrate. The substrate reagent was prepared at this 
laboratory as follows: 250 mg of o-dianisidine were added 
to 50 ml of distilled water. 1.0 ml Triton X-100 was added and 
the solution then topped up to 100 ml with distilled water. Just 
before use 2.0 ml of the o-dianisidine solution was topped 
up to 10 ml with acetate buffer solution. 0.15 ml of serum 
was incubated with 3.0 ml of substrate reagent in a cuvette 
positioned in a spectrophotometer. The change in absorbance 
at 460 nm with time was observed. The enzyme activity was 
reported as units/ml, based on the molar absorption coef-
ﬁ  cient of o-dianisidine consumed.
Determination of superoxide dismutase 
(SOD1) activity in erythrocytes
Superoxide dismutase activity in erythrocytes (SOD- 
525 units) was determined at the Department of Pharmacology 
and Toxicology, University of Iceland, with a spectropho-
tometric assay (Bioxytech®, SOD-525) as described by 
Nebot and colleagues.11 The superoxide dismutase activity 
in the erythrocytes of both the patients and their controls 
was determined the same day. The assay is based on the 
SOD-mediated increase in the rate of auto-oxidation of Neuropsychiatric Disease and Treatment 2009:5 57
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5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzofluorene 
(BXT-01050) in aqueous alkaline solution. The kinetic mea-
surement of 525-nm absorbance is performed for 1 minute 
upon the addition of BXT-01050. The SOD activity was 
determined from the ratio of the auto-oxidation measured 
in the presence and in the absence of the sample. One SOD 
activity unit (U-525) has been deﬁ  ned as the activity that 
doubles the auto-oxidation background. The reagents used 
in the analyses were obtained from Oxis International, Inc., 
Portland, OR, USA.
Ceruloplasmin speciﬁ  c oxidative activity
The speciﬁ  c oxidative activity of CP in serum (oxidative 
activity relative to mass) was calculated as CP oxidative 
activity, units/ml, divided by the value of CP concentration. 
This is represented as units/μmol*10−4 in Table 1.
Statistics
Ceruloplasmin concentration, oxidative activity and speciﬁ  c 
oxidative activity were normally distributed in the controls. 
The GGT activity and copper concentration did not pass 
normality tests (D’Augostino and Pearson omnibus and 
Shapiro–Wilk), but did so after the transformation to loga-
rithmic ﬁ  gures. The SOD1 activity did not pass the normality 
tests, and transformation of the SOD1 values to logarithmic 
ﬁ  gures did not change this. For this reason, SOD1 activity 
in heterozygotes and the age- and gender-matched controls 
were compared by using Wilcoxon’s two-sample test. The 
student’s two-way t-test was used for comparing the results 
of the logarithmic ﬁ  gures of GGT and copper and for the 
determinations of CP concentration, oxidative activity and 
speciﬁ  c oxidative activity in the heterozygotes and their 
age- and gender-matched controls.
The calculations were done by GraphPad Prism®, but 
Figure 1 was made by Med Calc®. The null hypothesis was 
rejected for P values  0.05.
Results
The results of the determinations on the WD patients, heterozy-
gotes, and their controls are represented in Table 1 and Figure 1.
Discussion
There was no signiﬁ  cant difference in the activity of GGT 
in the heterozygotes compared with the controls. One WD 
patient had raised GGT. This patient was diagnosed with 
liver cancer shortly after the time of the study, probably as 
a late complication of WD.
All the Icelandic WD patients had lowered copper in 
plasma and lowered CP concentration and CP activity in 
serum. The SOD1 activity in erythrocytes was normal in the 
WD patients, although the SOD1 activity in all but one patient 
was above the median value of the control group for the 
heterozygotes (Figure 1). This could reﬂ  ect mild intracellular 
copper retention in spite of the lowered copper in plasma, 
lowered CP determinations in serum and the copper-chelating 
treatment in the WD patients.
In this study the CP concentration, CP oxidative activity 
and CP speciﬁ  c oxidative activity (activity related to mass, 
reﬂ  ecting the quality of the protein) in serum were not 
signiﬁ  cantly different in the heterozygotes compared with 
the control group. This is in line with earlier studies.4,5,12 
Furthermore, the copper in plasma was not signiﬁ  cantly 
Table 1 GGT activity, copper concentration, CP concentration, CP oxidative activity, CP speciﬁ  c oxidative activity and SOD1activity 
in 20 heterozygotes for Wilson disease with their age- and gender-matched controls. The number of pairs is indicated and the P values 
of the comparisons of the means. The null hypothesis was rejected for values  than 0.05. The results of same determinations are also 
shown in the 5 homozygotes known in Iceland at the time of the study
Determinations Heterozygotes
Mean (range)
Controls
Mean (range)
P-values Homozygotes
Mean (range)
GGT units/l (serum) 25 (12–86) 28 (16–68) 0.104*² 61 (14–194)
Copper conc. μmol/l (plasma) 18 (11–32) 19 (12–33) 0.507**¹ 3.2 (2–5)
CP conc. μmol/l (serum) 2.3 (1.3–3.6) 2.3 (1.4–4.1) 0.539¹ α
CP oxidative activity units/ml (serum) 137 (82–211) 152 (65–227) 0.170¹ 29 (17–36)
CP speciﬁ  c oxidative activity units/μmol *10−4 (serum) 6.2 (3.7–11.1) 6.9 (2.8–9.4) 0.392¹ β
SOD1 activity, SOD 525 units (erythrocytes) 360 (265–476) 328 (250–437) 0.066*² 352 (319–376)
Abbreviations: GGT, gamma glutamyl transpeptidase; CP, ceruloplasmin; SOD1, Cu-Zn superoxide dismutase.
Notes: ¹Student’s two sample t test, in a normally distributed sample; ² Wilcoxon’s two sample test, were the sample is not normally distributed; *Not normally distributed 
after logarithmic transformation; **Normally distributed after logarithmic transformation; α Under the det.lim. of the laboratory; β Not calculated as the CP concentration 
is not available.Neuropsychiatric Disease and Treatment 2009:5 58
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different between the heterozygotes compared with 
controls. Still, it was possible to see a trend toward lower 
CP oxidative activity in the heterozygotes. As described 
in the Introduction, Cox and colleagues showed that after 
an oral and intravenous dose of labelled copper (64Cu and 
67Cu), the incorporation rates into CP were slower in het-
erozygotes than in normal controls but faster than in the 
homozygotes for WD.4 In a study by Gollan and colleagues, 
lowered CP-speciﬁ  c oxidative activity was encountered in 
two families with WD, in both the patients (homozygotes) 
and the heterozygotes, while this was not the case in other 
WD families studied by these authors.13 This reﬂ  ects that 
the quality of CP can vary between different families with 
WD (reﬂ  ecting different mutations of the ATP7B). The 
results of our study (although not signiﬁ  cant) point toward 
lesser quality of the CP in the heterozygotes in the Icelan-
dic families with WD compared with individuals with no 
family history of WD.
The Icelandic heterozygotes did not show any symptoms 
in either the liver or the nervous system, indicating that 
a slightly deranged copper metabolism does not promote 
disease. Still, there are reports of mild movement disorders 
in heterozygotes for WD.14–17 As CP concentration and 
oxidative activity have been found to be signiﬁ  cantly lower 
in Alzheimer disease and Parkinson disease,18–20 the question 
arises whether the heterozygotic relatives of the WD patients 
are more likely to develop these neurodegenerative diseases 
compared with the general population, as they get older. In 
that context, the division of the heterozygotes and their con-
trols into age groups would have been of interest, but this was 
not considered meaningful in this study as the sample was 
very small. Our earlier studies have not shown a correlation 
between the CP concentration or activity in serum or SOD1 
activity in erythrocytes and age in healthy individuals,19,20 
which is in accordance with other authors.21,22
SOD1 activity in erythrocytes was not signiﬁ  cantly different 
between the heterozygotes and the controls (P = 0.066), but 
there was a trend toward higher SOD1 activity in the heterozy-
gotes (Figure 1). The trend toward higher SOD1 activity in the 
heterozygotes in the present study can reﬂ  ect a slight tendency 
to lower copper excretion and thus higher intracellular copper 
in the heterozygotes compared with controls.
SOD-525 units
SOD1 activity in erythrocytes
500
450
400
350
300
250
Heterozygotes Controls
Figure 1 Distribution of individual values of SOD1 activity in heterozygotes and controls (SOD-525 units in erythrocytes). The central box represents the values from the 
25th to the 75th percentile (314–414 in heterozygotes and 289–368 in the controls). The middle line represents the median in the patients and the controls (354 and 325), 
respectively. The horizontal lines represent the lowest and highest value, (265 and 476) in heterozygotes, (250 and 437) in controls.
Abbreviation: SOD1, Cu-Zn superoxide dismutase.Neuropsychiatric Disease and Treatment 2009:5 59
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Thus, taken together, although the Icelandic heterozygotic 
carriers do not develop WD, they may exhibit mild abnormali-
ties in copper metabolism, as described in the results above. An 
important limitation is the low power of this study as the sample 
is small and it would clearly be of interest to investigate bigger 
groups of heterozygotes for WD to further conﬁ  rm this trend. 
Moreover, the heterozygotes in this study are rather young or 
middle-aged. In a bigger study group it would be relevant to 
see if neurodegenerative diseases would be more prevalent 
with rising age in this group than in the general population. 
The WD patients show similar defects in CP determinations 
as described earlier from different WD families although the 
Icelandic mutation of the Wilson gene is unique.
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